CurveBeam AI (ASX:CVB) does not expect any material impact from the Trump administration's tariffs, saying most of the components it uses come from US partners, according to a Tuesday filing with the Australian bourse.
The company, which makes point-of-care specialized medical imaging equipment, conducts its manufacturing activities within the US. The majority of components derived from its US partners represent around 75% of the cost of goods, per the filing.
"Based on an initial risk assessment, the company does not expect material adverse effects from the tariff changes," CurveBeam said in the filing.
The company's shares were up 6% in recent trade.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。